How much runway is enough in 2026

Why 18 months no longer works

Healthcare sales cycles have lengthened, not shortened. A Series A raised for 18 months of runway routinely runs out with the next round of milestones still six months away. The result is a punishing bridge market.

The 30-month floor

For clinical AI, medical devices pre-clearance, and any company with a regulated go-to-market, we now advise founders to target 30 months of runway at each round. That is the honest interval between meaningful, financeable milestones.

Implications for round sizing

This will push seed rounds toward $5–8M and Series A rounds toward $20–30M for most healthcare companies. Founders should model this before they walk into a pitch and be prepared to defend it with milestone plans.

The volatility founders are underpricing

The 18-month rule assumed a reasonably predictable fundraising cadence and a reasonably predictable regulatory or reimbursement timeline, and neither assumption holds as reliably as it once did for healthcare startups. A single delayed FDA response, a payer policy reversal, or a slower-than-expected pilot-to-contract conversion can each independently add six to nine months to a plan that looked fully financed a year earlier.

Founders who model runway against a single expected timeline, rather than a distribution of plausible timelines, consistently find themselves back in a financing conversation earlier than they had told their board to expect. That mismatch between stated plan and actual outcome is itself a credibility cost that compounds in future raises.

What a 30-month plan actually buys

A 30-month runway is not primarily about surviving longer in an absolute sense; it is about being able to walk into the next fundraise from a position where the company does not need the capital urgently. Investors price desperation, whether or not a founder says the word out loud, and a company with genuine optionality on timing consistently negotiates better terms than one that is visibly six weeks from a wire running out.

The 30-month floor also allows a company to absorb one full regulatory or clinical setback without a survival-level crisis, which in this sector is closer to the base rate than the exception. Building the plan around absorbing one setback, rather than around a setback-free path, is the core mental shift.

How this reshapes round construction

A longer runway target does not necessarily mean raising a much larger round on the same terms; it more often means renegotiating milestones so that the round is sized to a real inflection point rather than to a calendar interval. Some founders are structuring rounds with a smaller initial tranche and a pre-negotiated follow-on tied to a specific clinical or commercial milestone, which extends effective runway without diluting as heavily upfront.

The tradeoff is that milestone-tied structures require real discipline in defining a milestone that is unambiguous and hard to game, since a vague or easily-satisfied milestone defeats the purpose. Founders and investors who spend the extra weeks negotiating a precise milestone definition tend to have a much smoother follow-on process than those who leave it loosely worded.